PMN ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. (PMN) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $1.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -17.4% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.